| Aug 5 |
BioMarin: Q2 Earnings Snapshot
|
| Aug 5 |
BioMarin Pharmaceutical Non-GAAP EPS of $0.96 beats by $0.36, revenue of $712.03M beats by $49.76M
|
| Aug 5 |
BioMarin Announces 20% Y/Y Total Revenue Growth in the Second Quarter and Increase in Full-year 2024 Guidance
|
| Aug 4 |
BioMarin Pharmaceutical Q2 2024 Earnings Preview
|
| Aug 1 |
Travere Therapeutics (TVTX) Reports Q2 Loss, Tops Revenue Estimates
|
| Jul 31 |
Wall Street's Insights Into Key Metrics Ahead of BioMarin (BMRN) Q2 Earnings
|
| Jul 26 |
The Zacks Analyst Blog Highlights Sage Therapeutics, Biogen Agenus and BioMarin Pharmaceutical
|
| Jul 25 |
FDA agrees wider use of BioMarin’s BRINEURA for CLN2
|
| Jul 24 |
BioMarin gets expanded FDA approval for CLN2 therapy Brineura
|
| Jul 24 |
U.S. Food and Drug Administration Approves BioMarin's BRINEURA® (cerliponase alfa) for Children Under 3 Years with CLN2 Disease
|
